Department of Public Health and Clinical Medicine Umeå University, SE-901 87 Umeå, Sweden
www.phmed.umu.se
ISBN 978-91-7601-781-4 ISSN 0346-6612
Niklas Gunnarsson Chronic myeloid leukemia and cancer Umeå University2017
Full text
Department of Public Health and Clinical Medicine Umeå University, SE-901 87 Umeå, Sweden
www.phmed.umu.se
ISBN 978-91-7601-781-4 ISSN 0346-6612
Niklas Gunnarsson Chronic myeloid leukemia and cancer Umeå University2017
Related documents
Papers II and III demonstrate that anti-CD20 mono- clonal antibodies (mAbs) triggered ROS production by monocytes and neutrophils, which translated into reduced NK
The thesis work has comprised in vitro studies of interactions between NK cells and primary myeloid leukemic cells along with analyses of NK cell repertoires in a clinical trial
The thesis work has comprised in vitro studies of interactions between NK cells and primary myeloid leukemic cells along with analyses of NK cell repertoires in a clinical trial
The addition of HDC or other ROS inhibitors or scavengers rescued a significant proportion of NK cells (Figure 8B). These results support the hypothesis that
The aims were (I) to describe a European lower risk MDS population and the use of erythropoietin stimulation agents (ESA), (II) to describe the AML population in
The primary aim of the present thesis was to investigate the influence of CYP3A metabolic activity and cellular transport mediated by genetic variants of ABCB1 and ABCG2
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell
In paper I, we screened a population-based cohort of CLL patients (n=364) for TP53, NOTCH1, SF3B1, BIRC3 and MYD88 mutations using Sanger sequencing, and confirmed